Impact of Face Masks on 6MWD in Patients With Pulmonary Hypertension

July 18, 2022 updated by: Max Wissmueller, University Hospital of Cologne

Impact of Face Masks on the Six Minute Walking Distance in Pulmonary Hypertension Patients During the COVID-19 Pandemic: A Prospective, Randomized Cross-over Study

Pulmonary hypertension (PH) is classified according to the Nice Classification into different etiologies, including pulmonary arterial hypertension (PAH), a disease of the pulmonary arteriolar vasculature (Class I), and forms of pulmonary hypertension associated with left heart disease (Class II), lung disease (Class III), pulmonary artery obstructions including chronic pulmonary embolism (Class IV) or other less common causes (Class V). Patients with PH are at risk in the current COVID 19 pandemic.

The course of the disease and the prognosis of the patients are assessed on the basis of various parameters and therapy is adapted accordingly. In addition to clinical, echocardiographic and laboratory examinations, cardiopulmonary performance tests such as the 6-minute walking distance (6MWD) are of particular significance. According to the ESC/ERS guidelines for PH and the recommendations of the Cologne Consensus Conference, exercise performance is a central criterion for prognostication and treatment decisions.

During the COVID-19 pandemic, hospitals require the constant use of face masks for patients, in most cases also during the 6 minute walking test. We suspect a performance-reducing effect of face masks, thus impacting the results of the 6MWD. A systematic error in the assessment of cardiopulmonary performance should be revealed by comparing the results of the 6MWD with and without mask (particularly surgical mask and FFP2 mask).

Study Overview

Status

Completed

Detailed Description

Monocentric, prospective, randomized cross-over study in approximately 120 patients with PH (n=60 for surgical face mask versus no mask; n=60 for FFP2 mask vs. no mask) to evaluate the impact of face masks on 6MWD, Borg dyspnea score, and O2 saturation pre- versus post exercise. Patients are randomized to perform the test with vs. without mask first, and then cross over to the respective other condition.

The primary endpoint is the intra-individual difference in 6MWD with and without mask (analyzed for the whole study group, and for surgical mask and FFP2 mask seperately). Secondary endpoints include differences in Borg score, and O2 saturation.

Study Type

Interventional

Enrollment (Actual)

122

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cologne, Germany
        • University Hospital of Cologne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Regular 6MWD in the last 24 months, at least 1 test per 24 months
  • Pulmonary (arterial) hypertension according to the Nice Classification Type I-V
  • NYHA-WHO/FC I - III
  • Lung function test performed within 6 months
  • Age ≥18 years
  • Severity of symptoms and specific therapy stable during the last 4 weeks
  • General ability to participate in the study
  • Ability to give consent

Exclusion Criteria:

  • Contact allergy to face mask materials
  • Significant peripheral arterial occlusive disease (Fontaine ≥ IIb)
  • Muscular or orthopedic diseases of the lower extremities that contribute to reduced resilience
  • Relevant coronary heart disease (angina pectoris ≥ CCS II or positive stress test, myocardial infarction or bypass surgery within the last 3 months)
  • inability to perform the 6-minute walk test (mental, physical) or lack of ability to provide essential information (questionnaire, Borg level)
  • Uncontrolled high blood pressure (≥140/90 mmHg or ≥160/100 mmHg with 3 antihypertensive drugs) or resting heart rate ≥ 100 b.p.m.)
  • Fresh fractures / broken bones (within the last 3 months)
  • Not able to give consent Insufficient ability to walk (NYHA IV, immobility, other ailments)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: with mask (FFP2 mask or surgical mask)
Patient is Walking with mouth/nose-mask for 6 Minutes.
Patients conducting a six-minutes-walking test
Placebo Comparator: without mask
Patient is Walking without mouth/nose-mask for 6 Minutes.
Patients conducting a six-minutes-walking test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intra-individual difference in six-minute-walking-distance (6MWD) with versus without face mask
Time Frame: one day while follow-up visit in PAH-center
Patients repeat a walking-test, conducting 2 walks on one day while a Follow-Up-visit. Change in six-minutes-walking-distance will be measured intra-individually. Patients are walking without mask (control) and wearing a mask (intervention). Minimum 1 hour of rest in between control and intervention. A cross-over design is performed with randomization, if mask will be used in the first six-minutes-walking.
one day while follow-up visit in PAH-center

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PAH-specific Quality of life Baseline
Time Frame: while follow-up 1 day visit in PAH-center
PAH-specific Quality of life assessed by PAH-Sympact (Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire)
while follow-up 1 day visit in PAH-center
Depression Baseline
Time Frame: while follow-up 1 day visit in PAH-center
Depression assessed by PHQ9 (Patient Health Questionnaire, 1-27 points with higher depression-severity with higher total points)
while follow-up 1 day visit in PAH-center
Anxiety Baseline
Time Frame: while follow-up 1 day visit in PAH-center
Anxiety assessed by GAD7 (Generalized Anxiety Disorder Scale 7; 0-21 points with higher Anxiety-Symptoms with higher total points)
while follow-up 1 day visit in PAH-center
Intra-individual difference in pSO2 performing a six-minutes-walking-test (6MWT) with face mask
Time Frame: one day while follow-up-visit in PAH-center

Patients repeat a walking-test, conducting 2 walks on one day while a Follow-Up-visit. Change in pSO2 while the six-minutes-walking-test will be measured intra-individually. Patients are walking without mask (control) and wearing a mask (intervention). Minimum 1 hour of rest in between control and intervention. A cross-over design is performed with randomization, if mask will be used in the first six-minutes-walking.

The pSO2 is continuously documented while patients perform the walking test and while the first 3 Minutes of rest after walking.

one day while follow-up-visit in PAH-center
Intra-individual difference in Borg dyspnea score after a six-minutes-walking-test (6MWT) with versus without face mask
Time Frame: one day while follow-up-visit in PAH-center
Patients repeat a walking-test, conducting 2 walks on one day while a Follow-Up-visit. Dyspnea is assessed by Borg dyspnea score (Borg dyspnea score; 0-10 points with increasing dyspnea-severity with higher total points)
one day while follow-up-visit in PAH-center

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Max VJ Wissmueller, MD, University Hospital of Cologne

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2020

Primary Completion (Actual)

February 2, 2022

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

November 4, 2020

First Submitted That Met QC Criteria

February 24, 2022

First Posted (Actual)

February 25, 2022

Study Record Updates

Last Update Posted (Actual)

July 21, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2020_01
  • UoC Ethics 20-1581-1 (Other Identifier: University Hospital of Cologne)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe